secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091826
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q2 total revenue up 46% to $242M; net income $33.4M vs $1.1M last year
-----------------------------------------------------------------------------

- NUPLAZID net sales $157.4M (+11% YoY); DAYBUE net sales $84.6M (vs $23.2M YoY).
- Net income $33.4M ($0.20 EPS) vs $1.1M ($0.01 EPS) in Q2 2023.
- NUPLAZID FY guidance raised to $590-610M; DAYBUE lowered to $340-370M.
- Total revenue FY guidance revised to $930-980M (from $930M-$1.01B).
- Cash and investments $500.9M at June 30, 2024, up from $438.9M at Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017024091826/0000950170-24-091826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017024091826/acad-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer